Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
Rangering i aksjer
#4335
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
Aksjekurs
$3.87
Markedsverdi
$3.57B
Endring (1 dag)
-1.64%
Endring (1 år)
9.08%
Land
CN
Handel Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Kategori
Healthcare
Inntekter for Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Inntekter i 2026 TTM: 0
Ifølge Hubei Jumpcan Pharmaceutical Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Hubei Jumpcan Pharmaceutical Co., Ltd. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $309.05M | -24.26% |
| 2024 | $408.03M | -12.40% |
| 2023 | $465.78M | 28.11% |
| 2022 | $363.58M | 18.48% |
| 2021 | $306.87M | 35.13% |
| 2020 | $227.09M | -16.47% |
| 2019 | $271.87M | -5.40% |
| 2018 | $287.38M | 30.25% |
| 2017 | $220.64M | 40.80% |
| 2016 | $156.70M | 27.27% |
| 2015 | $123.13M | 26.13% |
| 2014 | $97.62M | 27.38% |
| 2013 | $76.64M | 66.50% |
| 2012 | $46.03M | 3,404.74% |
| 2011 | $1.31M | -0.73% |
| 2010 | $1.32M | 15.79% |
| 2009 | $1.14M | -13.96% |
| 2008 | $1.33M | -42.34% |
| 2007 | $2.30M | 28.76% |
| 2006 | $1.79M | 27.84% |
| 2005 | $1.40M | 13.48% |
| 2004 | $1.23M | -0.48% |
| 2003 | $1.24M | -50.58% |
| 2002 | $2.51M | -0.21% |
| 2001 | $2.51M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
